Eslicarbazepine acetate
 | |
| Systematic (IUPAC) name | |
|---|---|
|
(S)-10-Acetoxy- 10,11-dihydro- 5H-dibenz[b,f]azepine- 5-carboxamide | |
| Clinical data | |
| Pregnancy category |
|
| Legal status |
|
| Routes of administration | Oral |
| Pharmacokinetic data | |
| Excretion | ~90% renal |
| Identifiers | |
| CAS Number | 236395-14-5 |
| ATC code | N03AF04 |
| PubChem | CID 179344 |
| ChemSpider | 156110 |
| ChEMBL |
CHEMBL1067  |
| Chemical data | |
| Formula | C17H16N2O3 |
| Molar mass | 296.320 g/mol |
| |
| |
Eslicarbazepine acetate (brand names Aptiom, Zebinix, Exalief), abbreviated as ESL, is an anticonvulsant medication approved for use in Europe and the United States as an adjunctive therapy for epilepsy.[1][2]
Similarly to oxcarbazepine, ESL behaves as a prodrug to eslicarbazepine ((S)-(+)-licarbazepine).[3] As such, their mechanisms of action are identical.[4] However, there may be pharmacokinetic differences between the two drugs; for instance, ESL may not produce as high of peak levels of (S)-(+)-licarbazepine immediately after dosing as does oxcarbazepine, which could, in theory, improve tolerability.
Like oxcarbazepine, ESL may be used to treat bipolar disorder and trigeminal neuralgia.
See also
References
- ↑ "Press Announcements > FDA approves Aptiom to treat seizures in adults".
- ↑ "European Medicines Agency - Find Medicine - Zebinix".
- ↑ Rogawski MA (June 2006). "Diverse mechanisms of antiepileptic drugs in the development pipeline". Epilepsy Res. 69 (3): 273–94. doi:10.1016/j.eplepsyres.2006.02.004. PMC 1562526. PMID 16621450.
- ↑ Rogawski MA, Löscher W (July 2004). "The neurobiology of antiepileptic drugs". Nat. Rev. Neurosci. 5 (7): 553–64. doi:10.1038/nrn1430. PMID 15208697.
| ||||||||||||||
| ||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Tuesday, June 16, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.